Trials / Unknown
UnknownNCT04492293
An Efficacy and Safety Study of ICP-192 in Subjects With Bladder Urothelial Cancer
A Phase 2, Multicenter, Single Arm, Open-lable Study of ICP-192 in Subjects With Surgically Unresectable or Metastatic Bladder Urothelial Cancer With FGFR Genetic Aberrations.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 115 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a phase 2, multicenter, single arm, open-lable study of ICP-192. The purpose of this study is to evaluate efficacy of ICP-192 in subjects with surgically unresectable or metastatic bladder urothelial cancer.
Detailed description
bladder urothelial cancer
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-192 | ICP-192 is a white, round, uncoated table |
Timeline
- Start date
- 2020-05-27
- Primary completion
- 2024-12-31
- Completion
- 2025-06-30
- First posted
- 2020-07-30
- Last updated
- 2024-02-26
Locations
22 sites across 1 country: China
Source: ClinicalTrials.gov record NCT04492293. Inclusion in this directory is not an endorsement.